KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Average (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Equity Average for 14 consecutive years, with $1.0 billion as the latest value for Q2 2025.

  • On a quarterly basis, Equity Average rose 11.02% to $1.0 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $1.0 billion, a 11.02% increase, with the full-year FY2024 number at $978.6 million, up 8.27% from a year prior.
  • Equity Average was $1.0 billion for Q2 2025 at Supernus Pharmaceuticals, up from $1.0 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.0 billion in Q2 2025 to a low of $749.7 million in Q1 2021.
  • A 5-year average of $881.4 million and a median of $884.3 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: rose 24.03% in 2021, then rose 2.91% in 2024.
  • Supernus Pharmaceuticals' Equity Average stood at $813.2 million in 2021, then grew by 6.93% to $869.5 million in 2022, then increased by 5.45% to $916.9 million in 2023, then increased by 2.89% to $943.3 million in 2024, then rose by 11.02% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Equity Average are $1.0 billion (Q2 2025), $1.0 billion (Q1 2025), and $943.3 million (Q2 2024).